Skip to main content

Table 2 Associations between ITF2 methylation and clinicopathological features in tumor DNA. Analysis of 216 MSI-H and 216 MSS CRC patients from Ontario and Newfoundland

From: Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients

 

MSS (n = 216)

MSI-H (n = 216)

 

Unmethylated (%)

Methylated (%)

OR (95 % CI)a

P-value

Unmethylated (%)

Methylated (%)

OR (95 % CI)a

P-value

Age

        

 <50

24 (15.2)

6 (10.3)

1.552 (0.600–4.014)

0.361

24 (20.5)

14 (14.1)

1.567 (0.761–3.225)

0.220

 50+

134 (84.8)

52 (89.7)

  

93 (79.5)

85 (85.9)

  

Sex

        

 Male

73 (46.2)

26 (44.8)

1.057 (0.577–1.935)

0.857

64 (54.7)

36 (36.4)

2.113 (1.222–3.655)

0.007

 Female

85 (53.8)

32 (55.2)

  

53 (45.3)

63 (63.6)

  

TNM Stageb

        

 1

36 (22.8)

14 (24.1)

0.720 (0.606–0.856)

0.193

31 (26.5)

18 (18.2)

5.167 (0.499–53.450)

0.321

 2

78 (49.4)

32 (55.2)

  

57 (48.7)

55 (55.6)

  

 3

32 (20.3)

12 (20.7)

  

28 (23.9)

23 (23.2)

  

 4

12 (7.6)

0 (0.0)

  

1 (0.9)

3 (3.0)

  

Histological Gradeb

        

 Low

16 (10.8)

4 (7.5)

2.000 (0.482–8.295)

0.624

9 (13.8)

8 (13.1)

0.728 (0.215–2.459)

0.514

 Moderate

118 (79.7)

42 (79.2)

  

39 (60.0)

42 (68.9)

  

 High

14 (9.5)

7 (13.2)

  

17 (26.2)

11 (18.0)

  

Locationc

        

 Proximal

58 (37.9)

29 (50.9)

0.589 (0.319–1.089)

0.090

60 (89.6)

54 (87.1)

1.270 (0.432–3.735)

0.664

 Distal

95 (62.1)

28 (49.1)

  

7 (10.4)

8 (12.9)

  

Histological Typed

        

 Non-Mucinous

140 (90.3)

49 (84.5)

1.714 (0.705–4.167)

0.230

76 (66.7)

73 (75.3)

0.658 (0.360–1.202)

0.172

 Mucinous

15 (9.7)

9 (15.5)

  

38 (33.3)

24 (24.7)

  

MMR Protein Status

        

 Intact

143 (97.9)

55 (98.2)

0.867 (0.088–8.511)

0.902

21 (18.6)

9 (9.1)

2.283 (0.992–5.251)

0.048

 Deficient

3 (2.1)

1 (1.8)

  

92 (81.4)

90 (90.9)

  

MMR Germline Mutation

        

 No

157 (99.4)

58 (100.0)

0.730 (0.673–0.792)

0.544

89 (76.1)

74 (74.7)

1.074 (0.577–1.999)

0.822

 Yes

1 (0.6)

0 (0.0)

  

28 (23.9)

25 (25.3)

  

MLH1 Methylation

        

 Unmethylated

143 (96.0)

52 (100.0)

0.733 (0.674–0.798)

0.142

68 (58.1)

42 (42.4)

1.883 (1.095–3.238)

6.72x10-4

 Methylated

6 (4.0)

0 (0.0)

  

49 (41.9)

57 (57.6)

  

BRAF V600E Mutation

        

 No

141 (92.2)

51 (91.1)

1.152 (0.387–3.431)

0.799

70 (63.1)

50 (52.6)

1.537 (0.088–2.683)

0.130

 Yes

12 (7.8)

5 (8.9)

  

41 (36.9)

45 (47.4)

  

CIMP Status

        

 Negative

100 (96.2)

33 (84.6)

4.545 (1.208–17.100)

0.016

50 (61.7)

29 (47.5)

1.780 (0.908–3.489)

0.092

 Positive

4 (3.8)

6 (15.4)

  

31 (38.3)

32 (52.5)

  

Survival Status

        

 Alive

110 (69.6)

35 (60.3)

1.475 (0.790–2.755)

0.221

78 (66.7)

70 (70.7)

0.829 (0.464–1.478)

0.524

 Deceased

48 (30.4)

23 (39.7)

  

39 (33.3)

29 (29.3)

  
  1. aOdds ratio and 95 % confidence interval for methylated versus unmethylated
  2. bOR and 95 % CI given for lowest stage/grade versus highest stage/grade
  3. cProximal tumor location includes lesions up to and including the splenic flexure
  4. dMucinous histology includes the presence of any mucin within the tumor stroma
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us